[Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Medizinische Klinik und Poliklinik B, Universitätsklinikum Münster.
J
J
Heidemann
T
T
Kucharzik
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000209:etiology; D004351:Drug Resistance; D004361:Drug Tolerance; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab